Daily Newsletter

29 August 2023

Daily Newsletter

29 August 2023

Cantex commences brain metastases combo therapy trial

Azeliragon was discovered by vTv Therapeutics and is under development for Alzheimer’s disease.

August 29 2023

Cantex Pharmaceuticals has commenced an investigator-initiated Phase II clinical trial evaluating azeliragon capsule together with stereotactic radiosurgery in brain metastases patients.

The study is designed to determine whether the combined therapy can eliminate the use of dexamethasone for controlling swelling in the brain.

Safety and effectiveness of the combined therapy will also be evaluated in the study.

Cantex CEO Stephen Marcus said: “We are very excited to initiate enrolment into this important clinical trial.

“With the initiation of this Phase II clinical trial, Cantex expands the cancer indications for which azeliragon is being investigated, which now include active Phase II clinical trials in glioblastoma, breast cancer, pancreatic cancer, and a Phase II/III clinical trial in hospitalised Covid-19 patients to prevent acute kidney injury, accelerating azeliragon’s development as a treatment of very aggressive and difficult to treat cancers and other illnesses.”

Azeliragon blocks the interaction of S100A9 protein with receptor for advanced glycation end products (RAGE) thereby restoring sensitivity to radiation therapy.

It was discovered by vTv Therapeutics and is originally under development for Alzheimer’s disease. Cantex licensed global rights to azeliragon.

Recently, vTv Therapeutics announced plans to commence a Phase III clinical trial of cadisegliatin for treating type 1 diabetes.

Cadisegliatin, a liver-selective glucokinase activator, is indicated as an adjunct therapy along with insulin for reducing the number of hypoglycaemic events.

vTv also plans to expand the drug indications in treating type 2 diabetes, glioblastoma, primary mitochondrial myopathy, chronic obstructive pulmonary and renal diseases.

mRNA vaccines represent >40% of the authorized/approved COVID-19 vaccines and boosters in the 7 major pharmaceutical markets

There are currently 13 authorized/approved COVID-19 vaccines in the 7 major pharma markets. Currently, vaccine developers plan to launch updated boosters prior to the upcoming 2023 fall season to target the latest dominant strain, Omicron XBB.1.5. Per GlobalData analysis, mRNA vaccines will likely continue to dominate the market, though as the pandemic winds down, the global COVID-19 vaccines market is expected to decline.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close